FRESENIUS SE &/S (OTCMKTS:FSNUY) was upgraded by equities researchers at Sanford C. Bernstein from a “market perform” rating to an “outperform” rating in a research note issued on Tuesday, MarketBeat reports.
Other equities research analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of FRESENIUS SE &/S from a “hold” rating to a “sell” rating in a research note on Monday, March 9th. ValuEngine upgraded shares of FRESENIUS SE &/S from a “sell” rating to a “hold” rating in a research note on Tuesday, December 17th.
Shares of OTCMKTS FSNUY opened at $9.11 on Tuesday. FRESENIUS SE &/S has a fifty-two week low of $6.61 and a fifty-two week high of $14.80. The firm’s 50-day simple moving average is $11.38 and its 200 day simple moving average is $12.60. The stock has a market cap of $19.73 billion, a P/E ratio of 11.53 and a beta of 1.20.
FRESENIUS SE &/S Company Profile
Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.
Receive News & Ratings for FRESENIUS SE &/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FRESENIUS SE &/S and related companies with MarketBeat.com's FREE daily email newsletter.